155 related articles for article (PubMed ID: 32748048)
1. Comparison of PET/CT imaging with [
Uprimny C; von Guggenberg E; Svirydenka A; Mikołajczak R; Hubalewska-Dydejczyk A; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):935-936. PubMed ID: 32748048
[No Abstract] [Full Text] [Related]
2. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the
von Guggenberg E; Uprimny C; Klinger M; Warwitz B; Sviridenko A; Bayerschmidt S; di Santo G; Virgolini IJ
J Nucl Med; 2023 Jun; 64(6):859-862. PubMed ID: 36657979
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
4. CCK
Viering O; Günther T; Holzleitner N; Dierks A; Wienand G; Pfob CH; Bundschuh RA; Wester HJ; Enke JS; Kircher M; Lapa C
J Nucl Med; 2024 Mar; 65(3):493-494. PubMed ID: 37918864
[No Abstract] [Full Text] [Related]
5. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.
Asa S; Sonmezoglu K; Uslu-Besli L; Sahin OE; Karayel E; Pehlivanoglu H; Sager S; Kabasakal L; Ocak M; Sayman HB
Ann Nucl Med; 2021 Aug; 35(8):900-915. PubMed ID: 33993425
[TBL] [Abstract][Full Text] [Related]
7.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
8. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
9. Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.
Mahajan S; Shaha A; Grewal RK
Clin Nucl Med; 2018 Feb; 43(2):136-138. PubMed ID: 29261627
[TBL] [Abstract][Full Text] [Related]
10. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
Şahin E; Elboğa U
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.
Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L
Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
13. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin-Negative Neuroendocrine Tumor of the Thyroid on 68Ga DOTANOC PET-CT.
Tripathy S; Aggrawal S; Subudhi K; Kumar R; Narwal A
Clin Nucl Med; 2019 Sep; 44(9):e546-e547. PubMed ID: 31283604
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
18. Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by
Rotania M; Chabrier G; Imperiale A
Endocrine; 2019 Dec; 66(3):691-692. PubMed ID: 31478160
[No Abstract] [Full Text] [Related]
19. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).
Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S
Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467
[TBL] [Abstract][Full Text] [Related]
20. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
